08.08.2022 14:37

Zacks Investment Ideas feature highlights: Pfizer, Caterpillar, and Johnson & Johnson

For Immediate Release Chicago, IL – August 8, 2022 – Today, Zacks Investment Ideas feature highlights Caterpillar CAT, Johnson & Johnson JNJ, and Pfizer PFE.3 Blue-Chip Stocks With Rock-Solid DividendsInvesting in blue-chip stocks is a stellar strategy. Blue-chip stocks are companies that have consistently provided quality, reliability, and the ability to operate profitably in both good and bad times.Additionally, they generally carry robust dividend metrics – another major perk for investors.Three companies that fit the parameters – Pfizer, Caterpillar, and Johnson & Johnson – would all be excellent selections for investors seeking a stream of income paired with solid growth prospects.Let’s take a look at each company a little closer.Caterpillar Caterpillar is the world’s largest construction-equipment manufacturer. The company designs, develops, engineers, manufactures, markets, and sells machinery, engines, financial products, and insurance to customers. The company is a Zacks Rank #3 (Hold) with an overall VGM Score of an A.CAT has increased its dividend in 28 consecutive years, meeting the demanding requirements to join the elite Dividend Aristocrat group.The company’s annual dividend yields 2.6%, with a payout ratio sitting sustainably at 41% of earnings. Additionally, the company has a notable 8.9% five-year annualized dividend growth rate. As it stands, CAT is projected to register substantial growth. For the current fiscal year (FY22), the Zacks Consensus EPS Estimate resides at $12.70, reflecting a stellar 18% year-over-year uptick.The growth doesn’t stop there – CAT is forecasted to generate a mighty $57.5 billion in revenue in FY22, good enough for a double-digit 13% uptick from FY21 annual sales of $50.9 billion.Johnson & JohnsonJohnson & Johnson is an American multinational corporation that develops medical devices, pharmaceuticals, and consumer packaged goods. The company is a Zacks Rank #3 (Hold) with an overall VGM Score of an A.JNJ has increased its dividend for 60 consecutive years, making it not just a Dividend Aristocrat but a Dividend King as well – Dividend Kings have raised dividends for at least 50 straight years.The company’s annual dividend yields 2.6%, with a payout ratio sitting sustainably at 45% of earnings. Additionally, the company has a five-year annualized dividend growth rate of a notable 6%. Johnson & Johnson’s yield is much higher than the S&P 500’s.Of course, the titan is forecasted to grow at a solid pace – for the current fiscal year (FY22), earnings are expected to climb a respectable 3%.Pivoting to top-line projections, the annual revenue estimate of $95 billion for FY22 pencils in a modest 1.5% year-over-year uptick.PfizerPfizer is a multinational pharmaceutical and biotechnology corporation headquartered in New York City, well-known for its COVID-19 vaccine. The company is a Zacks Rank #3 (Hold) with an overall VGM Score of an A.Pfizer’s annual dividend yield sits enticingly at 3.2%, well above that of the S&P 500. In addition, the company’s payout ratio sits very sustainably at 26% of earnings, with an annualized five-year dividend growth rate of 4.7%.The company has stellar growth projections. For the current fiscal year (FY22), the Zacks Consensus EPS Estimate resides at $6.54, reflecting a sizable 48% double-digit year-over-year uptick.Top-line projections are rock-solid as well – PFE is forecasted to rake in $101.3 billion in revenue in FY22, a 25% year-over-year jump compared to FY21 annual sales of $81.5 billion.Bottom LineIn addition to solid dividend payouts and consistent growth, blue-chip stocks are typically less volatile as well, another major perk for investors.All three companies above had solidified themselves as titans in their respective industries.In addition, all three companies have repeatedly reported quarterly results above expectations, and current fiscal year growth is inspiring.For investors looking to add an additional layer of defense into their portfolio paired with solid growth and handsome dividend payouts, Caterpillar, Johnson & Johnson, and Pfizer would all fit those parameters.Why Haven’t You Looked at Zacks' Top Stocks? Our 5 best-performing strategies have blown away the S&P's impressive +28.8% gain in 2021. Amazingly, they soared +40.3%, +48.2%, +67.6%, +94.4%, and +95.3%. Today you can access their live picks without cost or obligation.See Stocks Free >>Media ContactZacks Investment Research800-767-3771 ext. 9339support@zacks.comhttps://www.zacks.comPast performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performancefor information about the performance numbers displayed in this press release.How to Profit from the Hot Electric Vehicle Industry Global electric car sales in 2021 more than doubled their 2020 numbers. And today, the electric vehicle (EV) technology and very nature of the business is changing quickly. The next push for future technologies is happening now and investors who get in early could see exceptional profits. See Zacks' Top Stocks to Profit from the EV Revolution >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Caterpillar Inc. (CAT): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research
Weiter zum vollständigen Artikel bei "Zacks"
Ausgewählte Hebelprodukte auf Caterpillar Inc.
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Caterpillar Inc.
Hebel wählen:
Quelle: Zacks

Nachrichten zu Pfizer Inc.

  • Relevant
  • Alle
  • vom Unternehmen
  • Peer Group
  • ?

Um Ihnen die Übersicht über die große Anzahl an Nachrichten, die jeden Tag für ein Unternehmen erscheinen, etwas zu erleichtern, haben wir den Nachrichtenfeed in folgende Kategorien aufgeteilt:

Relevant: Nachrichten von ausgesuchten Quellen, die sich im Speziellen mit diesem Unternehmen befassen

Alle: Alle Nachrichten, die dieses Unternehmen betreffen. Z.B. auch Marktberichte die außerdem auch andere Unternehmen betreffen

vom Unternehmen: Nachrichten und Adhoc-Meldungen, die vom Unternehmen selbst veröffentlicht werden

Peer Group: Nachrichten von Unternehmen, die zur Peer Group gehören

Analysen zu Pfizer Inc.

  • Alle
  • Buy
  • Hold
  • Sell
  • ?
14.09.2022Pfizer HoldJoh. Berenberg, Gossler & Co. KG (Berenberg Bank)
30.08.2022Pfizer Equal WeightBarclays Capital
26.08.2022Pfizer Equal WeightBarclays Capital
26.08.2022Pfizer BuyUBS AG
26.08.2022Pfizer NeutralGoldman Sachs Group Inc.
26.08.2022Pfizer BuyUBS AG
13.12.2021Pfizer BuyUBS AG
03.02.2021Pfizer kaufenDZ BANK
02.12.2020Pfizer OutperformRBC Capital Markets
16.10.2020Pfizer OutperformRBC Capital Markets
14.09.2022Pfizer HoldJoh. Berenberg, Gossler & Co. KG (Berenberg Bank)
30.08.2022Pfizer Equal WeightBarclays Capital
26.08.2022Pfizer Equal WeightBarclays Capital
26.08.2022Pfizer NeutralGoldman Sachs Group Inc.
29.07.2022Pfizer NeutralGoldman Sachs Group Inc.
03.05.2018Pfizer VerkaufenDZ BANK
16.05.2017Pfizer SellCitigroup Corp.
27.11.2012Pfizer verkaufenHamburger Sparkasse AG (Haspa)
28.08.2012Pfizer verkaufenHamburger Sparkasse AG (Haspa)
10.01.2012Pfizer verkaufenHamburger Sparkasse AG (Haspa)

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Pfizer Inc. nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"

Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"

Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
mehr Analysen
Neue Funktionen als Erstes nutzen
Sie nutzen finanzen.net regelmäßig? Dann nutzen Sie jetzt neue Funktionen als Erstes!
Hier informieren!
Börse Stuttgart Anlegerclub

Heute im Fokus

DAX dreht ins Plus -- US-Börsen mit Gewinnen -- Tesla-Auslieferungen enttäuschen -- Vodafone will Three UK übernehmen -- RWE plant Milliardenkauf- Accelleron-IPO, Porsche, Sixt. METRO im Fokus

Zunehmende Beschwerden über Deutsche Post. United Internet hebt Gewinnprognose an. Prosus bläst Übernahme von indischer Billdesk ab. Sixt erwartet "im Großen und Ganzen stabile Entwicklung". Intel stößt Börsengang der Autotochter an. JPMorgan senkt Rating für Lieferando-Mutter Just Eat Takeaway.com.


Glauben Sie, dass es in den kommenden sechs Monaten schwieriger wird, die eigenen Renditeerwartungen zu erzielen?

finanzen.net zero
finanzen.net zero



Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
Zur klassischen Ansicht wechseln